Technology evaluation: denosumab, Amgen

Bo Abrahamsen; Andy Y T Teng

Technology evaluation: denosumab, Amgen

Bo Abrahamsen
, Andy Y T Teng

20 Citationer (Scopus)

Abstract

Amgen, as part of its program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-kappaB ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.

Originalsprog	Engelsk
Tidsskrift	Current Opinion in Molecular Therapeutics
Vol/bind	7
Udgave nummer	6
Sider (fra-til)	604-10
Antal sider	7
ISSN	1464-8431
Status	Udgivet - dec. 2005
Udgivet eksternt	Ja

Citationsformater

@article{08961fa40f6f4b19a868fb4ce1fff170,

title = "Technology evaluation: denosumab, Amgen",

abstract = "Amgen, as part of its program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-kappaB ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.",

keywords = "Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Clinical Trials as Topic, Drug Evaluation, Preclinical, Drug Industry, Humans, Patents as Topic, RANK Ligand",

author = "Bo Abrahamsen and Teng, \{Andy Y T\}",

year = "2005",

month = dec,

language = "English",

volume = "7",

pages = "604--10",

journal = "Current Opinion in Molecular Therapeutics",

issn = "1464-8431",

publisher = "Thomson Scientific Ltd.",

number = "6",

}

TY - JOUR

T1 - Technology evaluation

T2 - denosumab, Amgen

AU - Abrahamsen, Bo

AU - Teng, Andy Y T

PY - 2005/12

Y1 - 2005/12

N2 - Amgen, as part of its program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-kappaB ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.

AB - Amgen, as part of its program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-kappaB ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Clinical Trials as Topic

KW - Drug Evaluation, Preclinical

KW - Drug Industry

KW - Humans

KW - Patents as Topic

KW - RANK Ligand

M3 - Journal article

C2 - 16370384

SN - 1464-8431

VL - 7

SP - 604

EP - 610

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

IS - 6

ER -

Technology evaluation: denosumab, Amgen

Abstract

Fingeraftryk

Citationsformater